Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Hu5F9 plus rituximab to overcome resistance in refractory lymphoma

Mark Roschewski • 15 Jun 2019
EHA 2019
Lymphoma Non-Hodgkin Lymphoma Magrolimab Rituximab

Lymphoma cells often use CD47 as a “don’t eat me” signal; if this antigen is blocked, the signal is removed and the lymphoma cell can be targeted by the immune system for autophagy. Here, Mark Roschewski of the National Cancer Institute, Bethesda, MD, discusses how the anti-CD47 antibody Hu5F9 can be used in combination with rituximab to overcome drug resistance in refractory lymphomas. This press briefing was recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Mark Roschewski

1:21
Response-adapted therapy with copanlisib and rituximab for previously untreated FL
Mark Roschewski • 8 Dec 2023
1:17
Ibrutinib & chemotherapy (TEDDI-R) in the treatment of secondary CNS lymphoma
Mark Roschewski • 8 Dec 2023
1:36
Analyzing circulating tumor DNA to determine remission in patients with lymphoma
Mark Roschewski • 8 Dec 2023
1:33
The difficulties of MRD detection in DLBCL
Mark Roschewski • 6 Sep 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals